Fortress Biotech Inc (FBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $62.70M
Last updated: Nov 17, 2026 at 4:15 PM ET
Fortress Biotech Inc (FBIO) Stock Chart
Fortress Biotech (FBIO) has a latest price of $1.82 on Nov 17, 2026, 59.8% below its 52-week high of $4.53. Its price fell 30.5% over the past 12 months. The month-end price fell 94.6% over the 10 years through Oct 2026, a compound annual decline of 25.3%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $71.21 in Jun 2017 and its lowest $1.45 in Sep 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart FBIO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for FBIO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 36.1%, and over 6 months it fell 28.1%. The month-end price rose 7.3% over the 3 years through Oct 2026, a compound annual rate of 2.4%.
| Period | Change |
|---|---|
| 1 month | -2.7% |
| 3 months | -36.1% |
| 6 months | -28.1% |
| 12 months | -30.5% |
| 12 months, with dividends | -30.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +7.3% | +2.4% |
| 5 years | -96.1% | -47.7% |
| 10 years | -94.6% | -25.3% |
Price by Year
Its best calendar year was 2019, when the price rose 198.8%, and its weakest was 2018, when it fell 78.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.92 | -47.5% |
| 2025 | $3.66 | +80.7% |
| 2024 | $2.02 | -32.7% |
| 2023 | $3.01 | -69.3% |
| 2022 | $9.82 | -73.8% |
| 2021 | $37.48 | -21.1% |
| 2020 | $47.53 | +23.3% |
| 2019 | $38.53 | +198.8% |
| 2018 | $12.89 | -78.4% |
| 2017 | $59.82 | +47.8% |
Trading Range
The price is 13.3% below its 50-day average of $2.10 and 32.5% below its 200-day average of $2.70.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.82 | |
| 52-week high | $4.53 | -59.8% |
| 52-week low | $1.71 | +6.4% |
| 50-day average | $2.10 | -13.3% |
| 200-day average | $2.70 | -32.5% |
Price Risk
Over 3 years, its largest fall from a peak was 64.3%.
| Measure | Value |
|---|---|
| 1-year beta | 1.39 |
| Largest fall, 1 year | -61.0% |
| Largest fall, 3 years | -64.3% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About FBIO
What is FBIO's 1-year price change?
Fortress Biotech's price fell 30.5% over the past 12 months. With dividends included, the 12-month total return was -30.5%.
What is FBIO's 5-year price change?
Fortress Biotech's month-end price fell 96.1% over the 5 years through Oct 2026, a compound annual decline of 47.7%. These figures leave out dividends.
What is FBIO's 52-week high and low?
Fortress Biotech's 52-week high is $4.53 and its 52-week low is $1.71. Its latest price of $1.82 on Nov 17, 2026 is 59.8% below the high.
What is FBIO's beta?
Fortress Biotech's 1-year beta against the S&P 500 is 1.39, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 61.0%.
Is the FBIO chart free?
Yes. Advanced Charting for FBIO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
FBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors